Dr. Nathanael Gray's Laboratory develops first-in-class chemical probes that are used to gain new biological insights into cellular processes that drive cancer and other diseases, and to pharmacologically validate potential clinically relevant targets. They take an integrative approach that combines medicinal chemistry, structural biology, biochemistry and molecular and cell biology to develop new therapeutic strategies. Their work has contributed to several approved and clinical stage drugs targeting BCR-ABL, Sphingosine-1-phosphate receptor (S1PR), EGFR, EML4-ALK and CDK7. The Gray lab has also developed numerous widely used chemical probes. The lab also develops new technologies for targeting challenging targets include ‘proximity-based’ therapeutics such as ligase recruiting degraders and covalent inhibitors targeting cysteine, lysine, tyrosine and aspartic acid.